AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CRISPR Therapeutics AG
Video analysis: CRSP
All videosNo video analysis for this stock yet. Request one from our team.
News: CRSP
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen provides a stable foundation with multi-billion dollar revenues and consistent cash flows. CRISPR Therapeutics offers high growth potential through its pioneering gene-editing technology.
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Why CRISPR Therapeutics Stock Rocked the Market Last Month
The FDA-approved drug it helped developed saw a nearly 80% sequential rise in sales. It also booked $10 million in upfront payments with a business partner.
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Where Will CRISPR Therapeutics Stock Be in 5 Years?
Successful pipeline development could substantially increase CRISPR's valuation. The upstart biotech has $2.36 billion to fund its expanding pipeline.
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:05 p.m.
Critical Contrast: Creative Medical Technology (NASDAQ:CELZ) vs. CRISPR Therapeutics (NASDAQ:CRSP)
Creative Medical Technology (NASDAQ: CELZ - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings. Institutional and Insider Ownership 1.4% of Creative
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case
CRISPR Therapeutics transitioned from speculative biotech to commercial stage with FDA approval of CASGEVY, validating its CRISPR/Cas9 platform. CRSP's pipeline targets multi-billion-dollar markets in cardiovascular, autoimmune, oncology, and diabetes, supported by a robust IP portfolio and major pharma partnerships. Current $5.6B market cap and $1.78B net cash position offer acquisition appeal, but most pipeline assets remain early stage and execution risks persist.
